Omeros reports final efficacy and safety data from the narsoplimab pivotal trial in hsct-tma

Seattle--(business wire)--omeros corporation (nasdaq: omer) today announced final data from its pivotal trial for narsoplimab in hematopoietic stem cell transplant-associated thrombotic microangiopathy (hsct-tma), an often-lethal complication of stem-cell transplantation for which there is no approved therapy. narsoplimab, an inhibitor of mannan-binding lectin-associated serine protease-2 (masp-2), the effector enzyme of the lectin pathway and activator of the coagulation cascade, is being stud
OMER Ratings Summary
OMER Quant Ranking